KalVista Pharmaceuticals (NASDAQ: KALV) has announced that it has entered into a licensing agreement with closely held Pendopharm to manage the regulatory approval process and commercialization of sebetralstat, an investigational oral on-demand treatment for hereditary angioedema (HAE).
The financial terms of the agreement were not disclosed.
In a statement, Ben Palleiko, CEO of KalVista, commented, “We look forward to collaborating with Pendopharm, whose deep knowledge of the Canadian market and proven track record make them a strong partner as we work to bring sebetralstat to people living with HAE. This partnership supports our broader goal of making sebetralstat available globally, as the first and only oral on-demand treatment that has the potential to transform HAE care.”
